Elizabeth Shpall, MD

The University of Texas MD Anderson Cancer Center

Disclosure(s): Adaptimmune: Advisor/Consultant; Affimed: License agreement; Axio: Advisor/Consultant; Bayer Helathcare Pharmaceuticals: Honoraria; Fibroblasts and FibrioBiologics: Advisor/Consultant; Navan: Advisor/Consultant; NY Blood Center: Advisor/Consultant; Takeda: License agreement

Poster(s):

• 2119 - Predictive Value of the Immunodeficiency Scoring Index for COVID-19 Related Outcomes in Hematopoietic Transplant Recipients
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2121 - The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2122 - The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET